Plain-English translation of NCT06866275 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , an experimental medication given by intravenous infusion (through an IV), to see if it can help improve social skills and interaction in boys with autism spectrum disorder. Half of the boys will receive the medication first, then a placebo (inactive infusion) later. The other half will receive the placebo first, then the medication. Researchers want to understand whether this treatment can make a real difference in how boys with autism connect with others.
Many children with autism struggle with social communication and interaction, and current treatments have limited effectiveness for these core challenges. This trial is exploring whether this medication might offer a new option to help improve these symptoms.
You likely qualify if…
You likely don't qualify if…
You would visit the study site multiple times over about 6 months. You would receive two intravenous infusions (one now, one in 4 weeks), then wait 8 weeks, then receive two more infusions of either the real medication or placebo depending on which group you're in. Between visits, you would need to wear sunscreen and protective clothing as a safety precaution. The study includes blood tests, urine tests, and assessments of your social and behavioral skills throughout.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United States